Noninvasive prenatal testing (NIPT), also known as cell-free DNA (cfDNA) screening, is a type of prenatal aneuploidy screening test. With a simple maternal blood draw, NIPT can noninvasively screen for the presence of fetal chromosomal aneuploidies as early as week 10. ACOG and SMFM recognize NIPT as a screening option for all pregnant women, regardless of age or risk.2
NIPT is as safe and simple as a blood draw.2
Greater than or equal to 99.9% sensitivity and specificity for trisomies 21, 18, and 13 as early as week 10.1
NIPT can be performed as early as week 10 of gestation until term.2
Download this Fast Facts Sheet to get a quick overview of NIPT, and see how early prenatal genetic insights can help your patients and inform your decision-making process.Download
With expanded NIPT, obtain a comprehensive view of all 23 chromosome pairs while limiting risk to your patient. Download this brochure to learn about expanded test options beyond chromosomes 21, 18, and 13.2,3Download
Adopting and implementing NIPT brings several advantages over conventional prenatal serum screening to inform your pregnancy management.4-8
False-positive rate: 0.13%7
unnecessary invasive procedure
False-positive rate: 4%9
unnecessary invasive procedures
Figures shown derived for a hypothetical population of 1000 pregnant women who would receive a false-positive result with each respective test, necessitating confirmatory diagnostic testing.
The VeriSeq NIPT Solution v2 is an in vitro diagnostic test intended for use as a screening test for the detection of genome-wide fetal genetic anomalies from maternal peripheral whole blood specimens in pregnant women of at least 10 weeks gestation. VeriSeq NIPT Solution v2 uses whole-genome sequencing to detect partial duplications and deletions for all autosomes and aneuploidy status for all chromosomes. The test offers an option to request the reporting of sex chromosome aneuploidy (SCA). This product must not be used as the sole basis for diagnosis or other pregnancy management decisions. Noninvasive prenatal testing (NIPT) based on cell-free DNA analysis from maternal blood is a screening test; it is not diagnostic. Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision.
Accuracy claims are specifically for VeriSeq NIPT Solution v2.